Complement 3-deficient mice are not protected against MPTP-induced dopaminergic neurotoxicity

被引:22
作者
Liang, Yajie
Li, Shurong
Guo, Qiang
Zhang, Yanliang
Wen, Can
Zou, Qiang [1 ]
Su, Bingyin
机构
[1] Chengdu Med Coll, Dept Histol & Embryol, Sichuan Key Lab Dev & Regenerat, Chengdu 610083, Peoples R China
[2] Chengdu Med Coll, Dept Immunol, Chengdu 610083, Peoples R China
[3] Mil Med Univ 3, Dept Neurobiol, Chongqing 400038, Peoples R China
[4] Chengdu Med Coll, Dept Pathol, Chengdu 610083, Peoples R China
基金
中国国家自然科学基金;
关键词
neuroinflammation; complement; 3; Parkinson's disease; knockout mice; MPTP;
D O I
10.1016/j.brainres.2007.08.033
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Recent studies have invoked inflammation as a major contributor to the pathogenesis of Parkinson's disease (PD). Emerging evidence indicated that components of complement system may be involved in such disorder and contribute to its development. We thus observed the influence of deficiency of complement 3 (C3), the key component of complement system, on the death of dopaminergic neurons in substantia nigra pays compacta (SNpc) and the loss of dopaminergic fibers in striatum induced by acute or chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Immunohistochemical staining of dopaminergic neurons in SNpc and neurochemical analysis of dopamine and its metabolites in striata revealed that there was no significant difference between the two genotypes. Longer survival time also indicated that C3 might not mediate the spontaneous recovery of dopaminergic fibers in mouse striaturn acutely challenged by MPTP. We conclude that, despite growing evidence indicating the involvement of complement system in the pathogenesis of PD, our data do not support a role for C3 in this established model of PD, as indicated by results from HPLC analysis and immunohistochemical staining. (C) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:132 / 140
页数:9
相关论文
共 38 条
[1]   ESTIMATION OF NUCLEAR POPULATION FROM MICROTOME SECTIONS [J].
ABERCROMBIE, M .
ANATOMICAL RECORD, 1946, 94 (02) :239-247
[2]  
[Anonymous], 2001, PAXINOS FRANKLINS MO
[3]   Expression of the complement C3a and C5a receptors after permanent focal ischemia: An alternative interpretation [J].
Barnum, SR ;
Ames, RS ;
Maycox, PR ;
Hadingham, SJ ;
Meakin, J ;
Harrison, D ;
Parsons, AA .
GLIA, 2002, 38 (02) :169-173
[4]  
Bezard E, 2000, SYNAPSE, V38, P363, DOI 10.1002/1098-2396(20001201)38:3<363::AID-SYN16>3.0.CO
[5]  
2-A
[6]   C3a expressed in the central nervous system protects against LPS-induced shock [J].
Boos, L ;
Szalai, AJ ;
Barnum, SR .
NEUROSCIENCE LETTERS, 2005, 387 (02) :68-71
[7]   Parkinson's disease: Mechanisms and models [J].
Dauer, W ;
Przedborski, S .
NEURON, 2003, 39 (06) :889-909
[8]   PARKINSONIAN SERUM CARRIES COMPLEMENT-DEPENDENT TOXICITY FOR RAT MESENCEPHALIC DOPAMINERGIC-NEURONS IN CULTURE [J].
DEFAZIO, G ;
DALTOSO, R ;
BENVEGNU, D ;
MINOZZI, MC ;
CANANZI, AR ;
LEON, A .
BRAIN RESEARCH, 1994, 633 (1-2) :206-212
[9]   Regulation of mast cell activation by complement-derived peptides [J].
Erdei, A ;
Andrásfalvy, M ;
Péterfy, H ;
Tóth, G ;
Pecht, I .
IMMUNOLOGY LETTERS, 2004, 92 (1-2) :39-42
[10]  
Furuya T, 2004, J NEUROSCI, V24, P1865, DOI 10.1523/JNEUROSCI.3309-03.2004